Breakthru Medicine emerges from stealth with $60M Series A for cancer drug development

Breakthru Medicine emerges from stealth with $60M Series A for cancer drug development

PHOENIX, Ariz., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Breakthru Medicine emerges from stealth with the close of a $60M Series A financing round following a prior undisclosed seed round. Breakthru was founded by biotech industry veterans Steve Potts, PhD, Mark Mulvihill, PhD, and Brian Barnett, MD, to deliver disruptive therapeutic modalities to cancer patients to address major unmet medical needs. Steve Potts has been involved in both the companion …

Sanofi's pipeline cuts; Breakthru Medicine raises $60M

✂️ Sanofi culls several programs: The move comes as part of its “regular portfolio reviews,” a spokesperson said in an email. One candidate affected was amlitelimab, which is no longer in mid-stage trials for alopecia ...